Affordable Access

deepdyve-link
Publisher Website

Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.

Authors
  • Zibelman, Matthew1
  • Pollak, Natasha2
  • Olszanski, Anthony J1
  • 1 Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, 333 Cottman Avenue, Philadelphia, PA 19111 USA.
  • 2 Department of Otolaryngology-Head & Neck Surgery, Temple University School of Medicine, 3401 North Broad Street, Kresge West, Philadelphia, PA 19140 USA.
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 01, 2016
Volume
4
Pages
8–8
Identifiers
DOI: 10.1186/s40425-016-0114-4
PMID: 26885370
Source
Medline
Keywords
License
Unknown

Abstract

Autoimmune inner ear disease has been previously associated with the therapeutic transfer of genetically engineered lymphocytes as an on-target effect of donor T-cells recognizing antigens on cells in the inner ear. It is important for physicians to have a high clinical index of suspicion for the appropriate recognition and management of any potential autoimmune toxicity with checkpoint inhibitors given the variability of presentation and unique aspects of toxicity.

Report this publication

Statistics

Seen <100 times